Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -117.0%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $644028 | $1M | $893119 | $67M | $383M | $2.6B | — | — |
| Enterprise Value | $-4400636 | $-3845719 | $-3186577 | $65M | $373M | $2.6B | — | — |
| P/E Ratio → | -0.09 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | 1537.95 | — | — | — |
| P/B Ratio | 0.11 | 0.20 | 0.16 | 23.11 | 33.19 | 126.31 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | 1499.31 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | 19.6% | — | — | — |
| Operating Margin | — | — | — | — | -3741.5% | — | — | — |
| Net Profit Margin | — | — | — | — | -3733.1% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -117.0% | -117.0% | -179.0% | -137.9% | -58.2% | -46.1% | — | — |
| ROA | -99.4% | -99.4% | -133.9% | -108.3% | -53.8% | -33.1% | -92.5% | -82.7% |
| ROIC | -404.2% | -404.2% | -399.9% | -522.8% | -429.7% | — | — | — |
| ROCE | -117.4% | -117.4% | -160.3% | -137.7% | -57.8% | -32.2% | -20070.3% | -479.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.04 | 0.12 | 0.04 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.84 | -0.71 | -0.64 | -0.83 | -0.93 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -8161.67 | -8161.67 | -8.38 | — | — | -8.49 | -44.32 | — |
Net cash position: cash ($5M) exceeds total debt ($120211)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.88 | 4.88 | 6.05 | 1.82 | 7.19 | 32.43 | 0.57 | 0.52 |
| Quick Ratio | 4.88 | 4.88 | 6.05 | 1.82 | 7.19 | 32.43 | 0.53 | 0.31 |
| Cash Ratio | 4.61 | 4.61 | 5.31 | 1.25 | 6.17 | 29.89 | 0.49 | 0.17 |
| Asset Turnover | — | — | — | — | 0.02 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | 1.85 | 1.16 |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | 0.0% | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $449043 | $45848 | $34266 | $31506 | $31425 | $19835 | $19835 |
Imminent liquidity and dilution
According to recent financial data, BJDX trades at a price-to-book ratio of 0.22, which suggests that the market is heavily discounting the company's asset base due to the absence of commercial revenue and the significant risks associated with its pre-revenue developmental stage in the diagnostic sector.
The low P/B multiple indicates that investors are assigning little value to the company's tangible assets, likely viewing them as specialized equipment with limited liquidation value. This valuation profile is typical for firms where the primary value resides in future regulatory milestones rather than current book value, suggesting that the market remains skeptical of the timeline to commercialization.
Based on reported figures, the company's ROIC has remained deeply negative, reaching -189.3% in 2026Q1, which highlights the severe erosion of invested capital as the firm continues to fund extensive R&D and clinical trial activities without any offsetting top-line revenue generation to support its operations.
The persistent decay in ROIC suggests that every dollar of capital deployed is currently failing to generate a return, reflecting the high-risk nature of the Symphony platform's development. Investors should monitor whether future clinical successes can reverse this trend, as the current level of capital destruction appears unsustainable without a fundamental shift in the business model.
As reported in financial statements, the current ratio has fluctuated significantly, dropping to 2.81 in 2026Q1 from a peak of 6.26 in 2024Q3, which indicates a tightening liquidity position as the company consumes its cash reserves to meet ongoing operational and clinical trial obligations.
While the current ratio remains above unity, the rapid decline in liquidity suggests that the company's ability to withstand further delays in regulatory approval is diminishing. This trend warrants close monitoring, as the firm may be forced to seek dilutive financing sooner than anticipated to maintain its current operational trajectory.
Compared to established diagnostic players like IDEXX Laboratories, which boasts a 42.5% ROIC, BJDX's negative return profile highlights a structural gap that reflects its pre-commercial status versus the mature, cash-generative operations of industry leaders that dominate the point-of-care diagnostic market.
The stark contrast in performance metrics underscores that BJDX is currently a speculative venture rather than an operational peer to large-cap diagnostic firms. Investors should recognize that the valuation gap is not merely a temporary discount but a reflection of the fundamental difference in risk and maturity between the two groups.
Analysts often misapply traditional profitability ratios like net margin to BJDX, which obscures the reality that the company is in a pre-revenue phase where negative margins are a structural feature of its current R&D-heavy business model rather than an indicator of poor operational efficiency.
Focusing on net margins for a company without revenue is misleading, as it fails to capture the progress of clinical milestones or the value of the underlying technology platform. Instead, investors should prioritize tracking the 'cash burn to clinical milestone' ratio, which provides a more accurate assessment of the company's survival and potential for future value creation.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BJDX stock.
Bluejay Diagnostics, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Bluejay Diagnostics, Inc.'s return on equity (ROE) is -117.0%. The historical average is -107.7%.
Based on historical data, Bluejay Diagnostics, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.